Drug Profile


Alternative Names: Linazolast; TMK 688; YM 257

Latest Information Update: 22 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Terumo
  • Developer Terumo; Yamanouchi
  • Class Antiasthmatics
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma; Atherosclerosis; Peptic ulcer; Skin cancer; Thrombosis

Most Recent Events

  • 01 Dec 1997 Phase-II clinical trials for Allergic rhinitis in USA (Unknown route)
  • 12 Sep 1997 A study in patients with allergic perennial rhinitis has been added to the adverse events and Obstructive Airways Disease therapeutic trials sections
  • 31 Oct 1996 A preclinical study has been added to the Obstructive Airways Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top